ADA Scientific Sessions 2026 Abstract

The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist in a Trial Inspired, and Wider, Population Individuals Living with Type 2 Diabetes: A Target Trial Emulation Study in CPRD

By Jonah J.c. Thomas, Gilberte Martine-Edith, Safoora Gharibzadeh, Pratik Choudhary

Study in peopleInterventions

The paper

Jonah J.c. Thomas, Gilberte Martine-Edith, Safoora Gharibzadeh, Pratik Choudhary

Leicester

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 2202-P

doi.org/10.2337/db26-2202-p

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs